Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2024 | Story André Damons | Photo Supplied
Maricel-van-Rooyen
Maricél van Rooyen, Project Manager for Research Information Management System (RIMS) and Research Ethics Adviser in the Directorate Research Development (DRD) at the University of the Free State (UFS), is the Programme Coordinator for a first-of-its-kind Southern African Research and Innovation Management Association (SARIMA)/ COP webinar on Environment and Biosafety Research Ethics.

The University of the Free State (UFS) is playing host to a first-of-its-kind webinar on Environment and Biosafety Research Ethics later this month with Maricél van Rooyen, Project Manager for Research Information Management System (RIMS) and Research Ethics Adviser in the Directorate Research Development (DRD), playing a pivotal role.

The webinar, which is part of the Eastern Region Community of Practice (COP), is taking place on 20 August. The target market for this virtual workshop is Biosafety and Environmental Research Ethics Committee (REC) chairpersons and members, professionals including research management professionals, administrators, research compliance managers and advisers, and research directors in Southern Africa and beyond.

Van Rooyen will be the Programme Coordinator for this Southern African Research and Innovation Management Association (SARIMA)/ COP Research Ethics Webinar, while Prof Robert Bragg, chairperson of the UFS Environmental and Biological Research Ethics Committee (EBREC), will give a presentation on the establishment of an EBREC.

The UFS, Stellenbosch University and the University of the Witwatersrand, form part of the COP which is a SARIMA (Southern African Research and Innovation Management Association) initiative to assist and share research ethics questions between institutions to empower research management and ethics compliance. SARIMA assisted with the online hosting and advertising of the webinar.

Purpose of the webinar

“Environment and Biosafety Committees in South Africa are a new idea, and only a few institutions in the country have such a committee. The UFS and the other institutions that will present at the workshop, take a leading role because they have already registered committees in place. We want to share and assist with establishing and operating such committees,” says Van Rooyen.

According to her, the need for the webinar arises from the upsurge of research and innovation in biotechnology and related fields over the past two decades that has led to exciting new discoveries in areas such as the engineering of biological processes, gene editing, stem cell research, CRISPR-Cas9 technology, Synthetic Biology, recombinant DNA, LMOs and GMOs, to mention only a few.

These advances, however, have generated concerns about biosafety, biosecurity and adverse impacts on biodiversity and the environment, leading to the establishment of Research Ethics Committees (RECs) at Higher Education and Research Institutions dedicated to reviewing research with implications for biosafety and the environment.

These EBRECs are in the early stages of their establishment and formalisation in South Africa, and there is much uncertainty about their composition, scope, procedures of decision-making and the principles that should guide their deliberations and assessments.

Leading the charge

The UFS took the lead in South Africa in ensuring international ethical compliance in this extended area of research, by establishing its own Environmental and Biological Research Ethics Committee (EBREC) six years ago. The UFS EBREC is one of only two such ethics committees at a South African university that combines the biosafety committee with environmental and biological research ethics to ensure ethics compliance in these fields.  The initiative started with Van Rooyen and her RIMS EthicsTeam, (Willem Kilian and Amanda Smith). The university is again taking charge with this webinar, which is a first of its kind.  

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept